All In MedTech

FDA Clearance Tracker · P990040

TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Sep 25, 2000 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Sep 25, 2000

Approved

Time to decision

437 days

Received Jul 16, 1999. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P990040
Device name
TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM
Applicant location
Miami, FL
Received
Jul 16, 1999
Decided
Sep 25, 2000
Decision
Approved
Supplements
37 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code KGG

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE TRUFILL(R) N-BUTYL CYANOACRYLATE (N-BCA) LIQUID EMBOLIC SYSTEM. THE DEVICE IS INDICATED FOR THE EMBOLIZATION OF CEREBRAL ARTERIOVENOUS MALFORMATIONS (AVMS) WHEN PRESURGICAL DEVASCULARIZATION IS DESIRED.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code KGG (tissue adhesive for use in embolization of brain arteriovenous malformations).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Cerenovus, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.